Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapi

GlobeNewswireMay 29 08:00 ET

We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l

Simply Wall StMay 24 11:37 ET

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $30

H.C. Wainwright analyst Douglas Tsao maintains $Cabaletta Bio(CABA.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 37.0% and

moomoo NewsMay 24 06:32 ET

We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth

Yahoo FinanceMay 22 15:21 ET

Express News | HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $30 Price Target

BenzingaMay 16 07:54 ET

Cabaletta Bio Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 136.41% HC Wainwright & Co. → $30 Reiterates Buy → Buy 04/05/2024 294.01% Cantor Fitzgerald → $

BenzingaMay 16 07:53 ET